FDA Approves Golimumab for Pediatric Ulcerative Colitis

Okay, ‍here’s a breakdown of the⁣ provided text, extracting the references and their details:

1. J&J‍ press release:

* Full Text: https://www.jnj.com/media-center/press-releases/u-s-fda-approves-simponi-golimumab-for-the-treatment-of-pediatric-ulcerative-colitis
*⁤ Source: Johnson &‍ Johnson (J&J) Media Center – Press release
* Topic: U.S.FDA approval of Simponi (golimumab) for pediatric ulcerative ⁣colitis.

2. ClinicalTrials.gov Study (PURSUIT 2):

* Full Text: https://clinicaltrials.gov/study/NCT03596645
* Identifier: NCT03596645
* Title: A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants⁤ With ‍Moderately to Severely Active Ulcerative Colitis (PURSUIT 2)
* Updated: September⁤ 15, 2025
* Accessed: October 8, 2025

3. (Incomplete) – Third Study:

* The ⁢text cuts off mid-sentence, but it refers to a study assessing the safety and pharmacokinetics of golimumab in pediatric patients. The full details are ‍not provided.

Key Observations:

* The⁤ references are formatted as numbered list items (1, 2, 3).
* The links are presented as both ⁢the full URL and as clickable links⁤ within the text.
* The text includes metadata related to the rendering of the links (astro-island, ssr, client, opts, await-children) wich is likely related to the website‍ framework used to display the content.
* The ⁢dates (Updated⁤ and Accessed) for the ClinicalTrials.gov ⁣study are in the future (2025), which is unusual and might indicate a placeholder or an ‍error in the data.